DESCRIPTION: (provided by the applicant): The goal of this project is to study
the surface glycoproteins of the African trypanosome, Trypanosoma brucei. The
variant surface glycoprotein (VSG) of bloodstream form parasites protects
subsurface structures from recognition by the host immune system. Switching
expression from one VSG to another (antigenic variation) allows the parasite to
survive in the host's bloodstream. Procyclin is the unusual protein that covers
the surface of the insect form of T. brucei. Our studies focus mainly on the
glycosyl groups of these proteins, especially the GPI anchors. The VSG GPI is
unusual in that it contains the fatty acid myristate.
Because trypanosomes have massive amounts of VSG they need large amounts of
myristate, which is a rare fatty acid in the host's bloodstream. In fact, it
appeared that there was not enough myristate in the serum to provide sufficient
myristate for GPI anchors. Only recently our lab found that trypanosomes
actually synthesize myristate, overturning the 30-year-old belief that they
cannot make fatty acids. The first specific aim is to study the mechanism of
myristate synthesis. Although trypanosomes are eukaryotes, the fatty acid
synthetic machinery resembles that of prokaryotes. Of special importance will
be studies aimed at testing inhibitors of fatty acid synthesis as candidate
anti-trypanosomal drugs. The second specific aim concerns the mechanism of GPI
anchoring and protein glycosylation. Previous studies along these lines have
been biochemical, but the proposed approach involves genetics. These studies
will involve the powerful new technique of RNA interference (RNAi) that
selectively silences trypanosome genes. The third aim involves the mechanism of
GPI myristoylation, by remodeling reactions. These experiments involve attempts
to purify and study a myristoyl transferase, using biochemical and genetic
techniques.
National Institute of Allergy and Infectious Diseases
CFDA Code
856
DUNS Number
001910777
UEI
FTMTDMBR29C7
Project Start Date
01-May-1984
Project End Date
30-April-2007
Budget Start Date
01-May-2003
Budget End Date
30-April-2004
Project Funding Information for 2003
Total Funding
$474,150
Direct Costs
$290,000
Indirect Costs
$184,150
Year
Funding IC
FY Total Cost by IC
2003
National Institute of Allergy and Infectious Diseases
$474,150
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI021334-20
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI021334-20
Patents
No Patents information available for 5R01AI021334-20
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI021334-20
Clinical Studies
No Clinical Studies information available for 5R01AI021334-20
News and More
Related News Releases
No news release information available for 5R01AI021334-20
History
No Historical information available for 5R01AI021334-20
Similar Projects
No Similar Projects information available for 5R01AI021334-20